PTC Therapeutics Q2 revenue more than doubles, raises 2026 outlook
PTCT•Q2 revenue and profit improve
PTC Therapeutics said second-quarter total revenue more than doubled year over year, driven by product sales. The company also swung to a second-quarter net profit from a loss a year ago.
Key details from the quarter included:
| Metric | Actual |
|---|---|
| Q2 Product Revenue | $238.82 mln |
| Q2 EPS | $0.92 |
| Q2 Net Income | $83.50 mln |
| Q2 Basic EPS | $1.01 |
| Q2 Operating Expenses | $211.54 mln |
| Q2 Operating Income | $148.98 mln |
Sephience, milestone payment and royalties drive results
Growth in product revenue was led by Sephience, which generated $151 mln in Q2 sales with broad uptake and international expansion.
Q2 results also included a $50 mln milestone payment from Novartis for the first patient dosed in the INVEST-HD Phase 3 study.
Royalty revenue from Roche's Evrysdi rose to $71.1 mln in Q2, up from $57.6 mln a year earlier.
2026 outlook raised
PTC raised its 2026 total revenue guidance to $1.18-$1.28 bln from a previous outlook, and raised 2026 product revenue guidance to $850-$950 mln from $750-$850 mln.
The company maintained its 2026 GAAP R&D and SG&A expense guidance at $775-$815 mln.
Analyst coverage showed the current average rating on the shares is "buy," with 12 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The median 12-month price target for PTC Therapeutics Inc is $93.00, about 24.8% above its July 29 closing price of $74.49.
